Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
Key Highlights
- ➤AHA presentation will detail cardiac outcomes after one nex-z dose in mixed-phenotype ATTRv-PN
- ➤ISA presentation will provide up to four years of ATTRv-PN follow-up data
- ➤Nex-z is being tested in Phase 3 MAGNITUDE and MAGNITUDE-2 trials
- ➤Nex-z received FDA Orphan Drug and RMAT designations
* Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial
* Presentation at ISA on Nov. 18 to include up to four years of follow-up data in patients with ATTRv-PN CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it will present new clinical data at two medical meetings in November. An analysis from the Phase 1 clinical trial of nex-z in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) with mixed phenotype (i.e. cardiac involvement) will be presented at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois. Long-term follow-up in patients with ATTRv-PN from the Phase 1 clinical trial will be presented at the International Society of Amyloidosis 2026 Symposium (ISA), taking place November 15-18 in Montevideo, Uruguay.
Get started
Create a free account to read the full story.